CA-YOU.COM
6.3.2024 02:17:34 CET | Business Wire | Press release
You.com announces its designation as one of the few new default browser options on iOS 17.4 for European Union users, alongside significant updates to its AI-powered mobile browsing app, You.com AI Search and Browse.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305667601/en/
Newly Revamped You.com AI Search and Browse App Now Available on iOS 17.4 in the European Union as Part of New Browser Choice Screen (Graphic: Business Wire)
The inclusion in the iOS browser choice screen today highlights You.com's increasing global popularity and dedication to delivering a cutting-edge AI-powered web search and browsing experience loved by its users.
“We're excited to share the latest update to our You.com AI Search and Browse app, now available as a default browser choice on iOS 17.4 for users throughout the European Union. As the only AI chat-native browser option on the new EU browser choice screen for iOS, You.com is setting a new standard for what a browser can do thanks to AI,” said Richard Socher, CEO of You.com.
Socher continued: “With the introduction of 'Ask AI' and a fresh, intuitive app design, we're not just updating features, we're enhancing how you find information online. You.com is more than another way to search and browse — it's an AI Assistant designed to make you more productive, creative, and extraordinary. We invite you to make You.com your default browser for a smarter way to find answers.”
What’s new:
- Introducing “Ask AI”: Dive into the future of search with our new "Ask AI" feature, delivering AI-powered answers complete with citations for a more informative and trustworthy browsing experience.
- A fresh, updated experience: Enjoy a cleaner, more intuitive interface with our updated app design, making navigation smoother and more enjoyable than ever before.
- Enhanced mobile homepage: Discover what's trending with an improved mobile home page that now offers trending suggestions, keeping you informed and engaged with the latest and most relevant content.
With You.com, users can say goodbye to endless scrolling through blue links and tedious websites. Search alone is inefficient for in-depth research, and ineffective at answering complex, multi-step questions. A conversational search experience powered by cutting-edge AI, You.com delivers immediate, comprehensive answers across any topic, supplemented by follow-up suggestions for deeper exploration.
You.com enhances the efficiency of finding information and enriches the quality of results with advanced AI functionalities that support text generation, content summarization, image creation, and more. You.com stands out for its powerful AI Modes, from its Research Mode which can browse and synthesize information from multiple websites simultaneously with extensive citations to its Genius Mode capable of multi-step complex problem solving.
Whether users prefer traditional search methods or the enriched, AI-enhanced search, You.com offers seamless management of searches, chats, and visited websites, with easy options for saving or deleting history. Linked citations further empower users to verify responses and delve into sources, ensuring a trustworthy and comprehensive browsing experience.
You.com also prioritizes privacy, offering ad-blocking, pop-up blocking, and tracking protection capabilities.
Download You.com today for free and experience a better way to search.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305667601/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom